Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress - 2Kristin Cavallari was the teen queen bee of 'Laguna Beach.' Now she's a 'cringey' mom.
- 3How to watch 'A Charlie Brown Christmas' for free in 2025
- 4Swap The Amalfi Coast For This Low-Cost Ligurian Seaside Town
- 5Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements
- Astonishing Deserts All over The Planet You Really want To Visit
- The Meaning of Breaking the Pen's Nib in Death penalties
- Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- Map shows more than 1,900 measles cases across U.S.
- VPN Administrations for Online Protection
- Gulf of Mexico oil spill spread hundreds of miles, killed wildlife and polluted Mexican reserves
- Watch This Glacier Race into the Sea
- Unsold Rams May Be Less expensive Than You Suspect
- Nestlé says 413,793 KitKat candy bars stolen en route from Italy to Poland
